Novo Nordisk A/S Announced Q1 2026 Earnings on May 6, 2026, Reporting "reported sales increased by 32%, reaching DKK 96.8 billion" for the quarter.
Novo Nordisk announced Q1 2026 sales rose 32% to DKK 96.8 billion. Adjusted sales fell 4% due to lower prices, offset by GLP-1 volume growth. Obesity care sales increased 22%, with Wegovy usage surpassing 1 million in the U.S. The company raised its 2026 guidance.